Advertisement

Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial

  • Nanda C. Krak
  • R. Boellaard
  • Otto S. Hoekstra
  • Jos W. R. Twisk
  • Corneline J. Hoekstra
  • Adriaan A. LammertsmaEmail author
Original Article

Abstract

Purpose

Quantitative measurement of tracer uptake in a tumour can be influenced by a number of factors, including the method of defining regions of interest (ROIs) and the reconstruction parameters used. The main purpose of this study was to determine the effects of different ROI methods on quantitative outcome, using two reconstruction methods and the standard uptake value (SUV) as a simple quantitative measure of FDG uptake.

Methods

Four commonly used methods of ROI definition (manual placement, fixed dimensions, threshold based and maximum pixel value) were used to calculate SUV (SUV[MAN], SUV15 mm, SUV50, SUV75 and SUVmax, respectively) and to generate “metabolic” tumour volumes. Test–retest reproducibility of SUVs and of “metabolic” tumour volumes and the applicability of ROI methods during chemotherapy were assessed. In addition, SUVs calculated on ordered subsets expectation maximisation (OSEM) and filtered back-projection (FBP) images were compared.

Results

ROI definition had a direct effect on quantitative outcome. On average, SUV[MAN], SUV15 mm, SUV50 and SUV75, were respectively 48%, 27%, 34% and 15% lower than SUVmax when calculated on OSEM images. No statistically significant differences were found between SUVs calculated on OSEM and FBP reconstructed images. Highest reproducibility was found for SUV15 mm and SUV[MAN] (ICC 0.95 and 0.94, respectively) and for “metabolic” volumes measured with the manual and 50% threshold ROIs (ICC 0.99 for both). Manual, 75% threshold and maximum pixel ROIs could be used throughout therapy, regardless of changes in tumour uptake or geometry. SUVs showed the same trend in relative change in FDG uptake after chemotherapy, irrespective of the ROI method used.

Conclusion

The method of ROI definition has a direct influence on quantitative outcome. In terms of simplicity, user-independence, reproducibility and general applicability the threshold-based and fixed dimension methods are the best ROI methods. Threshold methods are in addition relatively independent of changes in size and geometry, however, and may therefore be more suitable for response monitoring purposes.

Keywords

Standard Uptake Value Partial Volume Effect Order Subset Expectation Maximisation Threshold Method Maximum Pixel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, et al. The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510–8PubMedGoogle Scholar
  2. 2.
    Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997;38:1186–91PubMedGoogle Scholar
  3. 3.
    Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676–88PubMedGoogle Scholar
  4. 4.
    Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology1999;213:521–5Google Scholar
  5. 5.
    Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–95PubMedGoogle Scholar
  6. 6.
    Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464–71PubMedGoogle Scholar
  7. 7.
    Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumour control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024–35CrossRefPubMedGoogle Scholar
  8. 8.
    Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127–35CrossRefPubMedGoogle Scholar
  9. 9.
    Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumours using FDG PET. J Nucl Med 1999;40:1771–7PubMedGoogle Scholar
  10. 10.
    Lee JR, Madsen MT, Bushnel D, et al. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000; 21:685–90Google Scholar
  11. 11.
    Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000;7:647–55CrossRefGoogle Scholar
  12. 12.
    Hunter GJ, Hamberg LM, Alpert NM, et al. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996;37:950–5PubMedGoogle Scholar
  13. 13.
    Kole AC, Nieweg OE, Pruim J, et al. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and l-[1-11C]tyrosine PET. J Nucl Med 1997;38:692–6PubMedGoogle Scholar
  14. 14.
    Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848–57Google Scholar
  15. 15.
    Nakamoto Y, Zasadny KR, Minn H, et al. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 2002;4:171–8CrossRefPubMedGoogle Scholar
  16. 16.
    Chin BB, Lyengar S, Sabundayo BP, et al. Standardized uptake values in 2-deoxy-2-[18F]fluoro-d-glucose with positron emission tomography: clinical significance of iterative reconstruction and segmented attenuation compared with conventional filtered back projection and measured attenuation correction. Mol Imaging Biol 2002;4:294–300CrossRefPubMedGoogle Scholar
  17. 17.
    Visvikis D, Cheze-LeRest C, Costa DC, et al. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med 2001;28:1326–35CrossRefPubMedGoogle Scholar
  18. 18.
    Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519–27PubMedGoogle Scholar
  19. 19.
    Hoekstra CJ, Hoekstra OS, Stroobants SG, et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002;43:1304–09PubMedGoogle Scholar
  20. 20.
    Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med 2001;42:808–17PubMedGoogle Scholar
  21. 21.
    Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731–43Google Scholar
  22. 22.
    Yang SN, Liang JA, Lin FJ, et al. Differentiating benign and malignant pulmonary lesions with FDG-PET. Anticancer Res 2001;21:4153–57PubMedGoogle Scholar
  23. 23.
    Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PET images. Clin Nucl Med 1996;21:941–9CrossRefPubMedGoogle Scholar
  24. 24.
    Minn H, Zasadny KR, Quint LE, et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 1995;196:167–73PubMedGoogle Scholar
  25. 25.
    Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumours using FDG PET. J Nucl Med 1999;40:1771–7PubMedGoogle Scholar
  26. 26.
    Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–11PubMedGoogle Scholar
  27. 27.
    Mankoff DA, Dunwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806–14PubMedGoogle Scholar
  28. 28.
    Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470–7PubMedGoogle Scholar
  29. 29.
    Zasadny KR, Kison PV, Fransis IR, et al. FDG-PET determination of metabolically active tumour volume and comparison with CT. Clin Pos Imaging 1998;1:123–9CrossRefGoogle Scholar
  30. 30.
    Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer1997;15:2505–9Google Scholar
  31. 31.
    Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773–82CrossRefPubMedGoogle Scholar
  32. 32.
    Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836–9PubMedGoogle Scholar
  33. 33.
    Ramos CD, Erdi YE, Gonen M, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001;28:155–64CrossRefPubMedGoogle Scholar
  34. 34.
    Etchebehere EC, Macapinlac HA, Gonen M, et al. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of 18«F-FDG PET. Q J Nucl Med 2002;46:122–30PubMedGoogle Scholar
  35. 35.
    Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med 1999;26:591–8CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Nanda C. Krak
    • 1
  • R. Boellaard
    • 1
  • Otto S. Hoekstra
    • 1
  • Jos W. R. Twisk
    • 2
  • Corneline J. Hoekstra
  • Adriaan A. Lammertsma
    • 1
    Email author
  1. 1.Clinical PET CentreVU University Medical CentreAmsterdamThe Netherlands
  2. 2.Department of Clinical Epidemiology and BiostatisticsVU University Medical CentreAmsterdamThe Netherlands

Personalised recommendations